Ads
related to: tamoxifen vs raloxifene breast cancer risk reduction- Clinical Trial Results
Learn About Clinical Trial Results
In Patients Like Yours.
- Request A Rep
Request a Representative & Discover
More About Treatment Option.
- Ordering Information
Find Out More About Ordering
A Treatment For Your Patients.
- Prescription Info
Find Dosing Guides & Safety
Information Here.
- Clinical Trial Results
Search results
Results From The WOW.Com Content Network
One of the largest breast cancer prevention studies ever, [2] it included 22,000 women in 400 medical centers in the United States and Canada. [3] [4] [5] The study concluded that raloxifene caused fewer side-effects and less endometrial cancer than tamoxifen.
Jordan, V.C. A current view of tamoxifen for the treatment and prevention of breast cancer (Gaddum Memorial Lecture)" British Journal of Pharmacology 110:507-517, 1993. (257 citations as of May 26, 2021). Jordan, V.C. and Morrow, M.M. Tamoxifen, raloxifene and the prevention of breast cancer. Endocrine Reviews 20:253-278, 1999.
A report in September 2009, from Health and Human Services' Agency for Healthcare Research and Quality suggests that tamoxifen and raloxifene used to treat breast cancer, significantly reduce invasive breast cancer in midlife and older women, but also increase the risk of adverse side effects. [21]
It is used as endocrine therapy for women with estrogen or progesterone receptor-positive, stage 4 or recurrent metastatic breast cancer [7] and has demonstrated similar efficacy compared to tamoxifen as adjuvant treatment of breast cancer and in the treatment of metastatic breast cancer. [6] Raloxifene is used for the prevention and treatment ...
Arzoxifene is a highly effective agent for prevention of mammary cancer induced in the rat by the carcinogen nitrosomethylurea and is significantly more potent than raloxifene in this regard. Arzoxifene is devoid of the uterotrophic effects of tamoxifen, suggesting that, in contrast to tamoxifen, it is unlikely that the clinical use of ...
A report in September 2009 from Health and Human Services' Agency for Healthcare Research and Quality suggests that tamoxifen, raloxifene, and tibolone used to treat breast cancer significantly reduce invasive breast cancer in midlife and older women, but also increase the risk of adverse side effects. [47]